TY - JOUR
T1 - A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder
AU - Mcelroy, Susan L.
AU - Guerdjikova, Anna I.
AU - Blom, Thomas J.
AU - Crow, Scott J.
AU - Memisoglu, Asli
AU - Silverman, Bernard L.
AU - Ehrich, Elliot W.
PY - 2013/4
Y1 - 2013/4
N2 - Objective: To assess preliminarily the effectiveness of a novel opioid antagonist, ALKS-33, in binge eating disorder (BED). Method: In this randomized, placebo-controlled, flexible dose, proof-of-concept trial, 62 outpatients with BED and obesity received ALKS-33 (N = 26) or placebo (N = 36) for 6 weeks. Outcome measures of binge eating, body weight, and eating pathology were assessed. Results: A large decrease in binge eating episode frequency was observed following both ALKS-33 and placebo treatment. There was no significant difference between treatment groups in binge eating episode frequency or any other measure of binge eating, body weight, or eating pathology. Discussion: In this preliminary proof-of-concept study in BED, ALKS-33 did not separate from placebo. Although a failed trial cannot be excluded, the finding is consistent with earlier observations in bulimia nervosa with other opioid antagonists and suggests ALKS-33, at least when administered daily for 6 weeks, may not be efficacious for BED.
AB - Objective: To assess preliminarily the effectiveness of a novel opioid antagonist, ALKS-33, in binge eating disorder (BED). Method: In this randomized, placebo-controlled, flexible dose, proof-of-concept trial, 62 outpatients with BED and obesity received ALKS-33 (N = 26) or placebo (N = 36) for 6 weeks. Outcome measures of binge eating, body weight, and eating pathology were assessed. Results: A large decrease in binge eating episode frequency was observed following both ALKS-33 and placebo treatment. There was no significant difference between treatment groups in binge eating episode frequency or any other measure of binge eating, body weight, or eating pathology. Discussion: In this preliminary proof-of-concept study in BED, ALKS-33 did not separate from placebo. Although a failed trial cannot be excluded, the finding is consistent with earlier observations in bulimia nervosa with other opioid antagonists and suggests ALKS-33, at least when administered daily for 6 weeks, may not be efficacious for BED.
KW - binge eating disorder
KW - opioid receptor antagonist
UR - http://www.scopus.com/inward/record.url?scp=84875224535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875224535&partnerID=8YFLogxK
U2 - 10.1002/eat.22114
DO - 10.1002/eat.22114
M3 - Article
C2 - 23381803
AN - SCOPUS:84875224535
SN - 0276-3478
VL - 46
SP - 239
EP - 245
JO - International Journal of Eating Disorders
JF - International Journal of Eating Disorders
IS - 3
ER -